

Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone for the Treatment of Major Depressive Disorders

OSAKA, Japan, June 16, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") today announced that Sage Therapeutics, Inc. (Head Office: Massachusetts, USA, CEO: Barry Greene) and Biogen Inc. (Head Office: Massachusetts, USA, CEO: Michel Vounatsos) issued positive Phase 3 results of zuranolone (Shionogi development compound number: S-812217), a therapeutic candidate for major depressive disorders.

Please refer the link below for details of the announcement.

[Press release]

<https://www.businesswire.com/news/home/20210615005402/en/>

[Investor slides]

<https://investor.sagerx.com/static-files/ea6ab8b0-28e7-4f30-abfb-0222381eaf02>

In Japan, Shionogi is currently conducting Phase 2 clinical trials for the indications of depression, and plan to obtain breaking data during the 2nd quarter of the fiscal year 2021.

Shionogi is committed to “improve social productivity and extend healthy lifespans” as our key focus. We will endeavor to deliver breakthrough treatments for the patients of psycho-neurological diseases including depression, which still have high unmet medical needs, and contribute to improving the QOL of patients and their families.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>